Login to Your Account

CFDA head pledges to improve approval process, tackle backlog

By Pearl Liu
Staff Writer

Thursday, March 2, 2017

HONG KONG – The prolonged pending time for drug approvals in China that has long been a thorn in the side of drug- and medical device-makers should be drastically cut this year, as regulators take steps to become more efficient and shorten procedures.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription